Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Ultragenyx Pharmaceutical Inc. currently loses $68.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 11
in 84 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Ultragenyx Pharmaceutical’s results missed consensus on both revenue and EPS in the third fiscal quarter of 2026, reported November 3, 2026, even as revenue rose 8.2% to about $173.0 million from roughly $159.9 million a year ago. The top line was led by Product Revenue, which increased 10.5% to about $105.0 million, while Royalty revenue grew 4.6% to roughly $68.0 million. Revenue of $173.0 million trailed the $182.5 million estimate (-5.2%), and EPS of -$1.16 trailed the -$1.10 estimate by -$0.06, improving from -$1.81 a year ago. Profitability remained negative, with gross margin at about 82% and operating margin at roughly -64%, as gross profit came in around $141.0 million and operating income was -$110.0 million. Net income was -$118.0 million, narrowing 34.6% year over year from about -$180.4 million, while operating cash flow was negative at -$43.0 million. For the next period, consensus calls for EPS of -$0.74 on revenue of $226.4 million.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for rare and ultra-rare genetic diseases and trades on the NASDAQ under the ticker RARE. The company operates in biotechnology within the healthcare sector, sells marketed biologic products, and generated $673.0 million of revenue in FY2025.
Today's Snapshot
RARE closed 6.2% above yesterday's close, outperforming a weaker sector. Ultragenyx gained momentum from the MHRA, Britain’s medicines regulator, over its drug pipeline.
Trading Volume
Above 10d avg 4.1M
4.9M
vs S&P 500 Today
Strong Outperformance
+6.43%
Updated: November 18, 2026 at 21:22 UTC
RARE Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$16.32 - $21.73Buy
- RSI (14)60.24Neutral
- Stochastic %K (14, 3, 3)63.56Neutral
- MACD Level (12, 26)0.17Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.